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Abstract
Purpose Radiopeptide therapy using a somatostatin analogue
labelled with a beta emitter such as 90Y/177Lu-DOTATOC is a
new therapeutic option in neuroendocrine cancer. Alternative
treatments for patients with refractory disease are rare.
Here we report the first-in-human experience with
213Bi-DOTATOC targeted alpha therapy (TAT) in patients
pretreated with beta emitters.
Methods Seven patients with progressive advanced neuroen-
docrine liver metastases refractory to treatment with
90Y/177Lu-DOTATOC were treated with an intraarterial
infusion of 213Bi-DOTATOC, and one patient with bone
marrow carcinosis was treated with a systemic infusion of 213Bi-
DOTATOC. Haematological, kidney and endocrine toxicities
were assessed according to CTCAE criteria. Radiological
response was assessed with contrast-enhanced MRI and
68Ga-DOTATOC-PET/CT. More than 2 years of follow-up
were available in seven patients.
Results The biodistribution of 213Bi-DOTATOCwas evaluable
with 440 keV gamma emission scans, and demonstrated
specific tumour binding. Enduring responses were observed
in all treated patients. Chronic kidney toxicity was moderate.
Acute haematotoxicity was even less pronounced than with the
preceding beta therapies.
Conclusion TAT can induce remission of tumours refractory
to beta radiation with favourable acute and mid-term toxicity
at therapeutic effective doses.
Keywords Targeted alpha therapy (TAT) . 213Bi . 225Ac .
DOTATOC
Introduction
Well-differentiated neuroendocrine tumours (NETs) demon-
strate modest responses to conventional chemotherapy due to
their slow proliferation rate [1]. However, the expression of
somatostatin receptors by NET enables targeting with high-
affinity peptides. When these octreotide analogue peptides are
labelled with beta emitters such as 90Y [2] or 177Lu [3]
promising anti-tumour effects have been observed. Recently,
it has also been demonstrated that an improved tumour to
nontumour uptake of radiolabelled DOTATOC is achieved
after intraarterial administration in liver metastatic NET pa-
tients [4, 5]. However, patients with recurrences are usually
refractory to further treatment with beta radiation therapy.
Alpha radiation is characterized by high linear energy
transfer causing production of 2,000 – 7,000 ion pairs per
micrometre, leading to clustered double-strand DNA breaks
resulting in rapid cell death from even a single exposure to a
few alpha particles. The short range of alpha particles
(50 – 100 μm, i.e. about two or three cell diameters) limits
the effective range of treatment but also limits damage to
untargeted tissue. In contrast, beta-emitting radionuclides re-
sult in fewer than 20 ion pairs per micrometre and commonly
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cause only single-strand DNA breaks with less lethality and
more spillover effects caused by “crossfire” (Fig. 1). It has
already been demonstrated that the alpha emitter 213Bi is able
to overcome radioresistance to beta emitters in vitro [6]. The
alpha emitters 225Ac and 213Bi used to label the somatostatin
analogue DOTATOC have demonstrated already promising
antitumour effects with a favourable therapeutic range in
animal studies [7, 8]. Therefore, it seemed reasonable that
peptide targeted alpha therapy (TAT) with 213Bi-DOTATOC
delivered directly to metastases via intraarterial administration
might offer effective therapy to NET patients who have ac-
quired resistance to other therapies.
Here we report the first-in-human experience with 213Bi-
DOTATOC TAT in patients refractory to nonradioactive
octreotide and tandem therapy [9] with 90Y/177Lu-DOTATOC.
Materials and methods
Patients
This was a retrospective study of patients with differentiated
neuroendocrine tumours. The diagnosis was confirmed histo-
logically. These patients were not surgical candidates.
Systemic standard therapies such as chemotherapy in high-
grade or nonradioactive octreotide in low-grade tumours had
previously failed to stop tumour growth. Pretreatment also
included innovative peptide receptor radiation therapy
(PRRT) with octreotide analogues tagged with a beta emitter.
When patients showed progression with that treatment (new
lesions on PET or progression on CT >30 % within the
previous 2 – 6 months) TAT was offered as an alternative
therapy. Seven consecutive patients with prognosis-affecting
liver metastases arising from a pulmonary (one patient), pan-
creatic (four patients), enteric (one patient) or unknown pri-
mary (one patient) received intraarterial administration into
the common hepatic artery between November 2010 and
October 2011, and one patient with bone marrow carcinosis
arising from neuroendocrine prostate cancer was treated sys-
temically (Table 1, Supplementary Fig. 1). A positive tumour
somatostatin receptor expression was validated by 68Ga-
DOTATOC PET/CT. After the patients had given written
informed consent, salvage therapies (compassionate use) were
administered in accordance with the principles of the Helsinki
Declaration (paragraph 37 “Unproven Interventions in
Clinical Practice”) and our national regulations. The retro-
spective analyses of our observations were done with the
approval of our ethics committee.
Peptide, radionuclides and radiolabelling
DOTATOC (DOTA0-Phe1-Tyr3) octreotide was synthesized
as described by Otte et al. [10]. 225Ac was produced by
radiochemical extraction from 229Th as described by
Fig. 1 Comparison of alpha and beta emitters. a, c After binding of the
radionuclide-labelled octreotide analogue DOTATOC to the somatostatin
receptor subtype-2 (SSR2), which is overexpressed in NETs, the emitted
alpha particle causes high-density ionization effects, resulting mainly in
double-strand DNA breaks. In contrast, the beta particles emitted by
established radiopharmaceuticals mainly cause repairable single-strand
DNA damage. b, d The tissue range of alpha emitters (about 80 μm) is
approximately two cell diameters. The mean tissue range of the beta
emitter 90Y (3 mm) is approximately 75 cell diameters. Thus, alpha
emitters result in less “cross-fire” radiation to surrounding normal tissue
Eur J Nucl Med Mol Imaging (2014) 41:2106–2119 2107
T
ab
le
1
P
at
ie
nt
ch
ar
ac
te
ri
st
ic
s
Pa
tie
nt
G
en
de
r
H
is
to
lo
gy
P
re
tr
ea
tm
en
t
P
R
R
T
w
ith
be
ta
em
itt
er
s
(G
B
q)
D
ur
at
io
n
of
tu
m
ou
r
co
nt
ro
l
un
de
r
P
R
R
T
w
ith
be
ta
em
itt
er
s
(m
on
th
s)
2
1
3
B
ia
dm
in
is
tr
at
io
n
R
es
po
ns
e
(R
E
C
IS
T
)
C
ou
rs
e
of
fo
llo
w
-u
p
9
0
Y
1
7
7
L
u
C
yc
le
s
C
um
ul
at
iv
e
ac
tiv
ity
(G
B
q)
H
ig
he
st
si
ng
le
ac
tiv
ity
(G
B
q)
F
ol
lo
w
-u
p
du
ra
tio
n
(m
on
th
s)
O
ut
co
m
e
1
m
C
ar
ci
no
id
(K
i-
67
2
%
)
Su
rg
er
y
(p
ri
m
ar
y)
,
ra
di
ot
he
ra
py
(b
on
e)
,O
C
T,
St
r/
5-
FU
20
8
37
5
16
.0
7.
6
PR
(−
32
%
)
17
PF
S
2
f
P-
N
E
T
(K
i-
67
2
%
)
O
C
T
16
24
38
5
19
.5
7.
9
n.
a.
(d
is
se
m
in
at
ed
)
30
PF
S
3
f
A
ty
pi
ca
lp
ul
m
on
ar
y
ca
rc
in
oi
d,
gr
ad
e
II
I
(K
i-
67
25
%
)
Pl
/E
T
O
8
4
6
5
19
.3
7.
4
SD
34
PF
S
4
m
P-
N
E
T
(K
i-
67
5
%
)
Pl
,O
C
T
10
4
6
4
20
.8
6.
8
SD
12
PF
S
5
f
P-
N
E
T
(K
i-
67
15
%
)
O
C
T
18
14
19
4
13
.3
5.
9
C
R
>
28
(o
ng
oi
ng
)
C
R
6
m
N
eu
ro
en
do
cr
in
e
C
U
P
(K
i-
67
2
%
)
O
C
T,
Si
ro
13
2
11
5
20
.6
6.
7
SD
31
(o
ng
oi
ng
)
PF
S
7
f
P-
N
E
T
(K
i-
67
10
%
)
O
C
T
22
12
21
2
13
.7
10
.5
PR
(−
35
%
)
15
PF
S
8
m
N
eu
ro
en
do
cr
in
e
pr
os
ta
te
ca
nc
er
(K
i-
67
10
%
)
O
C
T
6
12
34
1
3.
3
3.
3
n.
a.
(b
on
e
m
ar
ro
w
ca
rc
in
os
is
)
6
(o
ng
oi
ng
)
PF
S
P
R
R
T
pe
pt
id
e
re
ce
pt
or
ra
di
on
uc
lid
e
th
er
ap
y,
P
-N
E
T
pa
nc
re
at
ic
ne
ur
oe
nd
oc
ri
ne
tu
m
or
,C
U
P
ca
nc
er
of
un
kn
ow
n
pr
im
ar
y,
O
C
T
oc
tr
eo
tid
e,
St
r
st
re
pt
oz
ot
oc
in
,5
-F
U
5-
fl
uo
ro
ur
ac
il,
P
Ip
la
tin
,E
TO
et
op
os
id
e,
Si
ro
si
ro
lim
us
C
R
co
m
pl
et
e
re
sp
on
se
,P
R
pa
rt
ia
lr
es
po
ns
e,
SD
st
ab
le
di
se
as
e,
n.
a.
no
ta
va
ila
bl
e,
P
F
S
pr
og
re
ss
io
n-
fr
ee
su
rv
iv
al
2108 Eur J Nucl Med Mol Imaging (2014) 41:2106–2119
Apostolidis et al. and Boll et al. [11, 12] and loaded on a
225Ac/213Bi radionuclide generator comprising AG MP-50
cation exchange resin (Bio-Rad) [13]. 213Bi was eluted as
BiI4
−/BiI5
2− ion at intervals of 2 – 3 h using 1.4 ml 0.1 M
HCl/0.1 M NaI. The eluate was added to a microwave vial
containing 350 μl 2 M TRIS buffer, 100 μl 20% ascorbic acid
and 15 μl of 2 mg/ml DOTATOC solution. The reaction
mixture was heated to 95 °C for 5 min using a microwave
synthesizer (Biotage® Initiator) and subsequently cooled to
<50 °C using pressurized air. Quality control was performed
by instant thin-layer chromatography (ITLC-SG; Pall Life
Sciences) with 0.05 M citric acid, pH 5, as solvent. Under
these conditions, unbound 213Bi moves with the solvent front
(Rf=1), while
213Bi-DOTATOC remains on the bottom of the
strip (Rf=0). Radiochemical purity was determined by mea-
suring the activity of the 440 keV gamma emission of 213Bi on
the upper and lower part of the ITLC strip in an automated
gamma counter (Berthold) using an energy window of
400 – 500 keV. Radiochemical purity was 99.7±0.3 %.
Specific activity was typically 80 MBq /nmol peptide at
the time of injection. Injections were performed typically
15±2 min after the end of generator elution. Before injection,
sterility of the final formulation was ensured via sterile filtra-
tion (Millex-GV, 0.20 μm;Millipore). The decay properties of
the 229Th/225Ac/213Bi radionuclide generator system are pre-
sented in Supplementary Fig. 2. Decay data are taken from
Nucleonica [14] and recent measurements [15–17].
Imaging
Staging and restaging procedures included contrast-enhanced
CT (CE-CT) and 68Ga-DOTATOC PET/CT. Contrast-
enhancedMRI (CE-MRI) using a hepatocyte-specific contrast
medium was also performed in patients with liver metastases.
In the first year restaging was performed every 3 months, and
from the second year every 6 months.
DOTATOC PET/CE-CT
The PET studies were acquired with a Biograph 6 PET/CT
scanner (SiemensMedical Systems, Erlangen, Germany). The
scanner resolution (according to NEMA2001) was
5.5 – 6.0 mm at full-width half-maximum (FWHM). The
transaxial field-of-view (FOV) of 605 mm was covered by a
512 matrix and the axial FOVof 162 mmwas covered with 65
slices per bed position. So the reconstructed voxel size was
1.2×1.2×2.5 mm. Imaging was started 60±10 min after the
.intravenous injection of 84 – 196 MBq of 68Ga-DOTATOC.
Static emission scans – corrected for dead time, scatter and
decay – were acquired from the vertex to the proximal legs,
requiring eight bed positions (4 min each). The images were
iteratively reconstructed with the ordered subsets expectation
maximization algorithm using four iterations with eight
subsets and Gaussian filtering of 5 mm FWHM. CE-CT was
performed as part of the PET/CT scan. Iodinated contrast
medium (Imeron 400; Bracco Diagnostics, Milan, Italy) was
injected at a flow rate of 4 ml/s. The liver and abdomen were
initially examined without contrast medium (130 keV, 30
mAs, CareDose), followed by an arterial phase (25 s delay)
and a portal venous phase (60 s delay). The low-dose CT scan
without contrast medium was used for attenuation correction.
Slice collimation was 6×1.0 mm, pitch factor 1.5, 110 keV, 95
mAs (CareDose), matrix 512×512 and rotation time 0.6 s,
reconstructed to a slice thickness of 1.25 mm and 0.8-mm
increment with a B30 kernel. Secondary raw data were
reformatted to a slice thickness of 5 mm with a 2.5-mm
increment in the coronal and axial views.
Magnetic resonance imaging
Magnetic resonance examinations were performed on a 1.5-T
MR system (Avanto, Siemens Medical Systems, Erlangen,
Germany). Unenhanced T1-weighted (gradient echo, TR
192 ms, TE 4.76 ms, 256×154 matrix) and T2-weighted
(HASTE, TR 801 ms, TE 69 ms, 384×213 matrix) fast
spin echo axial imaging was performed before diffusion-
weighted MRI and Gd-EOB-DTPA (Primovist®; Bayer
Schering, Berlin, Germany) administration for CE-MRI.
This hepatocyte-specific contrast medium was consid-
ered as the standard of reference for tumour delineation
[18]. Diffusion-weighted imaging was performed with a
breath-hold single shot echo planar sequence (TR
12,200 ms, TE 67 ms, FOV 430 cm, section thickness
5 mm, b values 50, 300 and 600 s/mm2, voxels 3.3×3.3×5,
EPI factor 112). The acquisition of delayed MR data after
contrast medium administration started with the intravenous
administration of 0.1 mmol/kg body weight of the contrast
medium Gd-EOB-DTPA with an infusion rate of 1.5 ml/s
followed by a 30-ml saline bolus. Imaging was performed
with a T1-weighted VIBE (volumetric interpolated breath-
hold examination) with TR 3.41 ms, TE 1.18 ms, slice-
thickness 4 mm and matrix 320×180, with 72 axial slices
and an acquisition time of 20 s for each dataset.
Treatment regimen
Preceding therapy with “cold” octreotide analogue was
discontinued for at least 6 weeks to exclude receptor occu-
pancy. For locally intensified liver treatment a 4F catheter
(Sidewinder S1; Terumo) was placed in the coeliac artery
via transfemoral access using the Seldinger technique with
local anaesthesia. Subsequently, a microcatheter (Progreat,
Terumo) was inserted coaxially and advanced to the common
hepatic artery or proper hepatic artery. In patients with ana-
tomical variation, the largest arterial feeder was cannulated.
The catheter was used to administer the 213Bi-DOTATOC.
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The patient with bone marrow carcinosis received an
antecubital infusion of the drug. 213Bi-DOTATOC was given
in increasing activities in cycles every 2 months (first cycle,
about 1.0 GBq; second cycle, about 1.5 GBq; third cycle,
2 – 4 GBq; fourth cycle, as available from the generator
system); cumulative and highest single activities are shown
in Table 1. To minimize renal toxicity, 1,000 ml of a
nephroprotective solution containing 30 g lysine and 30 g
arginine and 500 ml of Gelofusine was administered simulta-
neously, followed by 1,000 ml of saline as developed for
radiopeptide therapy with beta emitters [19].
213Bi-DOTATOC scintigraphy
Within the first 60 min after administration of 213Bi-
DOTATOC a planar whole-body scan and SPECT scan of
the liver were acquired with a Hawkeye gamma camera
(GE Healthcare, Little Chalfont, UK) using the standard
high-energy collimator and the 440 keV (±10 %) gamma
emission window. Scan speed was 8 cm/min for the whole-
body scan. SPECTwas done in the step-and-shoot mode with
120 projections every 3° and a 20-s acquisition time per step.
Specific binding of 213Bi-DOTATOC to the target structures
was validated by coreading of the 68Ga-DOTATOC PET scan
in comparison to the therapeutic gamma emission scans.
Pharmacokinetics
Blood samples were taken every 10 min after injection of the
first fraction of 213Bi-DOTATOC to assess plasma clearance.
Urine was collected for 45min after injection. Due to the short
half-life of 213Bi (46 min), the samples were immediately
evaluated by ex-vivo gamma counting (LB 951G; Berthold,
Bad Wildbad, Germany).
Toxicity
Acute haematological and chronic kidney toxicity are most
relevant in PRRT. Haematological toxicity was documented
according to the ECOC common toxicity criteria with blood
samples obtained at baseline and 48 h, then every week for the
first month after treatment and then every 2 weeks. Creatinine
clearance, blood urea nitrogen (BUN), and liver enzymes
were determined at least every 2 weeks after therapy. As
DOTATOC shows physiological uptake in the pituitary gland
and adrenals, we assessed endocrine toxicity with stimulation
tests, including thyroid-stimulating hormone after stimulation
with thyrotropin-releasing hormone, cortisol after stimulation
with synthetic adrenocorticotropic hormone, and follow-up
with serum catecholamines and the insulin-like growth factor
1, as recommended [20]. Patients underwent regular clinical
examination to check for unexpected side effects. Glomerular
filtration rate (GFR) [21] and tubular excretion rate (TER)
[22] were assessed with 51Cr-EDTA and 99mTc-MAG3, re-
spectively, at baseline, and 3 and 9 months after therapy.
Results
Pharmacokinetic data
Time–activity curves in blood, as presented in Supplementary
Fig. 3, were similar to data reported in the literature for
intravenously administered diagnostic somatostatin analogues
[23, 24]. Within the first half-life of the radionuclide an
average of 15.1±7.7 % (range 0.1 – 35.4 %) was eliminated
in the urine. The 440 keV gamma coemission of 213Bi
was sufficient to acquire evaluable planar and SPECTscans in
patients undergoing therapy at all injected activities.
Coreading with the pretherapeutic 68Ga-DOTATOC PET
scans validated specific binding at the tumour sites (Fig. 2).
Clinical course of patients
All patients had presented with a specific clinical challenge
when 213Bi-DOTATOC treatment was offered. Patient 1 with
multiple liver metastases received intraarterial therapy with
177Lu-DOTATOC. During follow-up, all except one metasta-
sis showed a response. However, the nonresponding lesion
showed rapid progression. The segmental branch of the feed-
ing liver artery was catheterized highly selectively to admin-
ister 1 GBq of 213Bi-DOTATOC. Subsiding restaging present-
ed partial remission including the previously nonresponding
lesion. The staging examination, angiography and restaging
are shown in Fig. 2a, d and Supplementary Fig. 4.
Subsequently the patient received four additional cycles of
213Bi-DOTATOC to a cumulative administered activity of
16 GBq. Patient 2 presented with highly disseminated meta-
static NET in the liver embedded in only small bridges of
healthy tissue. With their tissue range of several millimetres,
we hypothesized that beta emitters would probably have
caused radiation-induced failure of the remaining normal liver
parenchyma. 213Bi-DOTATOC was administered in
five cycles (19.5 GBq) by intraarterial injection. Liver en-
zymes returned to normal within 6 weeks and a substantial
radiological response was seen (Fig. 3). No acute liver toxicity
was observed. At the time of this report, this response had
been maintained for 30 months. Myelodysplastic syndrome
(MDS) was diagnosed 24 months after TAT, i.e. 5 years after
the first PRRT with 90Y-DOTATOC. Six months later, MDS
progressed into acute myeloid leukaemia (AML) and the
patient died.
Patient 3 was a 40-year-old woman with a pulmonary
carcinoid with hepatic metastases. Pathology of the resected
pulmonary specimen revealed moderate to undifferentiated
grade II/III disease (Ki-67 30 %). Under carboplatin/
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etoposide therapy the tumour progressed in the liver.
Subsequent locoregional infusion of 90Y-DOTATOC also
failed to halt progression. Imaging revealed the acute danger
of occlusion of the liver vein and the lower caval vein.
Therefore, this patient received, 19.3 GBq 213Bi-DOTATOC
divided into five cycles administered through a hepatic artery
catheter. A partial response was observed in the liver and the
response had beenmaintained for 34months at the time of this
report (Fig. 4). Patient 4 was referred to our department with
hepatic encephalopathy due to extensive liver metastases.
After intraarterial administration of 213Bi-DOTATOC to a
cumulative dose of 20.8 GBq, the patient was stable for 1 year
without a further hepatic event and then extrahepatic progres-
sion was diagnosed. Patient 5 failed to respond to convention-
al somatostatin analogue therapy but demonstrated a partial
response in the liver and pancreatic primary tumour to the first
three cycles of 90Y-DOTATOC, but then became refractory.
Liver metastases (proper hepatic artery) and the primary tu-
mour (gastroduodenal artery) were simultaneously accessible
by 213Bi-DOTATOC injection into the common hepatic artery.
After receiving 13.3 GBq 213Bi-DOTATOC intraarterially into
the shared feeder, complete responses were observed in the
liver and the primary, which had been maintained for
28 months at the time of this report (Fig. 5).
Fig. 2 Diagnostic 68Ga-DOTATOC PETscans in NET patients 1, 2 and 6
(a, b, c). d In patient 1 the largest lesion was highly selectively cannulated
for intraarterial administration of 213Bi-DOTATOC (top left); 440 keV
SPECT scan (bottom left) and whole-body planar (right) scans 45 min
after injection demonstrate peak uptake in the target lesion in liver
segment 6. e Patient 2 received two therapeutic injections, one into liver
segments 5 – 8 (top left) and one into segment 4a/b (top right); 440 keV
emission scans (bottom left and right) 045 min after injection show the
impact of intraarterial administration for fast tumour targeting and region-
ally intensified peptide accumulation. f In whole-liver treatment (patient
6) the hepatic biodistribution of 213Bi-DOTATOC is the same as the
distribution of 68Ga-DOTATOC, but in comparison to systemic treatment
spares the spleen
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Patient 6 presented with multiple progressive bulky liver
metastases. Under therapy with 90Y-DOTATOC some parts of
the tumour became necrotic but the major mass remained
active (Fig. 2c). In escalating doses he received a cumulative
dose of 20.6 GBq 213Bi-DOTATOC regionally into the liver
artery. The previously hyperarterialized lesions changed to a
devascularized mass, which showed stable disease after a
follow-up of 31 months at the time of this report. Patient 7
presented with liver and bonemetastases, but progressive liver
metastases were considered to determine the prognosis. This
patient had a history of grade IV haematotoxicity (thrombo-
cytes <25,000/μl) after treatment with 90Y-DOTATOC. After
receiving 13.7 GBq 213Bi-DOTATOC into the hepatic artery,
substantial partial responses were observed in the liver and
also the bone (Fig. 6) with striking disappearance of bone
marrow lesions but with only grade II haematotoxicity. The
Fig. 3 Patient 2 with disseminated liver metastases. a–c Initial findings.
Coronal (a) and transaxial (b) slices through the liver performed with a
hepatocyte-specific contrast medium. Metastases appear as “black holes”
against the enhanced normal liver parenchyma. In the diffusion-weighted
image (c), metastases show high signal intensities, while normal liver
appears dark. d–f After three cycles of 213Bi-DOTATOC to a cumulative
dose of 12 GBq, most of the liver parenchyma has recovered to a normal
appearance. The imageswith hepatocyte-specific contrast medium appear
homogeneous (d, e), and most of the disseminated diffusion restrictions
have diminished (f)
Fig. 4 Patient 3 with the acute danger of occlusion of both the liver veins
and the lower caval vein due to a large lesion in the upper central liver (a,
MR image) which was addressed by locoregional DOTATOC therapy
administered into the proper hepatic artery (b, digital subtraction
angiogram). Intense 68Ga-DOTATOC uptake and uptake of contrast
medium for CT was present in the initial staging (c, fused PET/CT
image). Only PET-negative, morphologically cystic residuals were found
6 months after therapy (d, fused PET/CT image)
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patient had maintained the liver response for 24 months at the
time of this report; extrahepatic progression occurred after
15 months.
Due to the promising “systemic side-response” and the low
acute haematotoxicity in patient 7, a systemic treatment
consisting of 3.3 GBq of 213Bi-DOTATOC was offered to
Fig. 5 Patient 5 before therapy (a–c) and after three cycles of 213Bi-
DOTATOC (d–f) to a dose of 4 GBq. aBeta-resistant residuals in the liver
(long arrows) and primary tumour (short arrow) are present in the
DOTATOC PET maximum intensity projection image. b CE-CT image
with the primary tumour outlined in red. c In the MR image with
hepatocyte-specific contrast medium, the liver metastases appear as black
cavities against the enhancing normal liver parenchyma. d–f After three
cycles of 213Bi-DOTATOC to a dose of 4 GBq, the lesions have dimin-
ished on the PET image (d) and CT image (e). Also on the MR image (f),
the residual lesion has almost disappeared as shown by the growth of
normal hepatocytes demonstrated by the uptake of the hepatocyte-specif-
ic contrast medium
Fig. 6 Patient 7 with an extensive tumour burden in the left liver lobe and
multiple lesions in the right lobe, as well as disseminated bone marrow
metastases predominantly in the spine and pelvis. These are demonstrated
in coronal and sagittal 68Ga-DOTATOC-PET maximum intensity projec-
tions (a). As expected, liver metastases showed significant shrinkage after
administration of 10.5 GBq of 213Bi-DOTATOC into the common hepatic
artery. Additional systemic efficiency resulting from the 213Bi-
DOTATOC reaching the systemic circulation after the first pass of the
liver was noted after 6 months in that most of the bonemarrowmetastases
had also diminished (b)
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patient 8, who suffered from diffuse bone infiltration from
neuroendocrine prostate cancer. Radiological treatment re-
sponse in non-solid tumours is not assessable, but despite an
advanced tumour spread, including disseminated bone mar-
row involvement, no relevant acute haematological side ef-
fects were observed and the patient was still alive after more
than 12 months follow-up at the time of this report (Fig. 7).
Toxicity
The mean TERs from 99mTc-MAG3 were 251 ml/min,
179 ml/min and 152 ml/min/1.73m2 body surface area at
baseline, 1 year after therapy and 2 years after therapy, respec-
tively. The mean GFRs from 51Cr-EDTA were 115 ml/min,
101ml/min and 83ml/min at baseline, 1 year after therapy and
2 years after therapy, respectively. Serum creatinine and BUN
were unchanged in all but one patient, who had a creatinine
value between 1 and 1.5 times the upper limit of normal
2 years after therapy. Due to the small number of patients,
we present the individual values for blood cell count, TER,
GFR and creatinine in each patient in the Supplementary
material (Supplementary Fig. 5). Acute haematological toxic-
ity was low. One patient with a previous history of grade IV
thrombopenia with 90Y-DOTATOC therapy developed grade
II thrombopenia with 213Bi-DOTATOC. The acute changes in
blood were grade 0/I in the other patients. During the long-
term follow-up, three patients developed chronic anaemia. In
patient 2 MDS/AML was diagnosed consecutively.
Erythropoietin levels in the lower normal range were found
in patient 3 (grade II anaemia, onset between 12 and 24months
after TAT) and in patient 7 (grade I/II anaemia, onset
12 months after TAT). The beginning of anaemia was
Fig. 7 Patient with bone
marrow carcinosis arising from
neuroendocrine prostate
cancer. After systemic therapy
with 3.3 GBq 213Bi-DOTATOC
only grade I thrombopenia
(>100.000/μl), grade I
neutropenia (neutrophils
>2,000/mm3) and grade I total
WBC (>3,000/mm3) were
observed 2 weeks after therapy
and recovered until week 4. Red
blood cells, haemoglobin
gammaGT and creatinine showed
no relevant change within
5 months (circles platelets,
triangles haemoglobin, inverted
triangles red blood cell count,
black squares total white blood
cell count, white squares absolute
neutrophil count, grey squares
absolute lymphocyte count,
hexagons creatinine, diamonds
gammaGT)
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correlated with late effects on TER or GFR and not related to
the time of treatment. Only patient 3 was symptomatic and
showed a favourable response to substitution of erythropoietin
(Epoetin Alfa Hexal). Therefore anaemia was interpreted as a
side effect on endocrine kidney function rather than on bone
marrow function. The other hormones and endocrine stimula-
tion tests (pituitary, thyroid, adrenals, androgens), as described
in the Materials and methods section, were neither systemat-
ically nor relevantly changed. In patient 3 Graves’ disease was
diagnosed 1 year after the last treatment cycle and has to be
considered therapy-associated because thyroid cells can also
express somatostatin receptors.
Discussion
Here we report the first-in-human experience with 213Bi-
DOTATOC TAT in NET patients refractory to nonradioactive
octreotide and 90Y/177Lu-DOTATOC. It was possible to im-
age the biodistribution of the therapeutic compound with
conventional 440 keV scintigraphy scans. Tumour binding
was comparable to that in diagnostic SSR imaging with
68Ga-DOTATOC (Fig. 2). Therefore, we concluded that the
in vivo stability and pharmacokinetics of 213Bi-DOTATOC
are sufficient and comparable to those of DOTATOC labelled
with other radionuclides. The clearance patterns of the time–
activity curves obtained with ex-vivo gamma-counting of
blood and urine samples were similar to previously reported
values for intravenously administered diagnostic somatostatin
analogues [23, 24]. The time–activity blood values from ve-
nous blood samples following intraarterial injection should
represent the amount of peptide that has passed the target
organ and reached the systemic circulation and should repre-
sent a parallel shift to that seen in the time–activity curve
following intravenously administration. However, we have
previously observed that the relevance of the first-pass effect
depends on the tumour burden in the liver and differences
between patients are higher for the intraarterial administration
route [4]. Sufficient in vivo stability of DOTATOC labelled
with the beta emitter has already been reported [2, 10]. In vitro
autoradiolysis of 213Bi-DOTATOC is prevented with ascorbic
acid. However, in contrast to beta-DOTATOC, the alpha de-
cay might translate into damage to the peptide. Nevertheless,
once the alpha particle is emitted, the fate of the peptide is only
of limited interest, as tumour targeting is only pivotal as long
as the molecule is radioactive.
The reported patient cohort was rather heterogeneous, be-
cause this was not a clinical trial with prospectively defined
inclusion criteria but represented the experience with surro-
gate treatments offered individually to patients in challenging
situations. Due to the limited clinical experience with TAT the
first patient was treated with a highly selective administration
into the tumour feeding artery of a single rapidly progressive
metastasis. In this first patient we were able to demonstrate
that it is possible to overcome the resistance to beta treatment
without significant acute toxicity. The next three patients were
in a life-threatening situation when they received their first
cycle of liver-selective TAT. In patient 3 an acute risk of vessel
occlusion was resolved successfully (Fig. 4). In long term
follow-up the progression-free survival was 36 months. This
is a remarkable clinical result. In contrast, the 2-year overall
survival of patients with undifferentiated pulmonary carci-
noids refractory to etoposide/carboplatin is <20 % if treated
with FOLFIRI or topotecan [25]. Patient 4 was scheduled for
liver-directed radionuclide therapy after an episode of hepatic
encephalopathy. While the liver metastases demonstrated a
positive response to the regionally intensified arterial therapy,
the patient showed extrahepatic progression. However, due to
improved liver function, the experimental TAT was stopped
and he was able to receive chemotherapy again which was still
effective for his bone metastases.
Patient 5 showed partial remission after the initial cycles of
90Y/177Lu-DOTATOC, but then no further tumour shrinkage
of the residual masses was achieved. Due to the favourable
acute and mid-term toxicity observed in our first TAT patients,
we individually offered TAT to this patient and achieved long-
lasting complete remissions in both the primary tumour and
liver metastases. Hepatic arterial infusion of TATwas indicat-
ed in patient 7 as disseminated liver involvement was consid-
ered the leading factor in the overall prognosis. Surprisingly,
in addition to the expected liver response, we also found “side-
efficacy” to various small bone marrow lesions. As the tumor-
al accumulation maximum (Umax) of intravenously adminis-
tered DOTATOC is about 70 min after injection (with 80 % of
Umax reached 45 min after injection), we did not anticipate
sufficiently fast tumour targeting and did not expect to achieve
a reliable tumour-to-blood dose ratio with a short half-life
radionuclide such as 213Bi (45.6 min) [24]. However, after
we observed a response of bone marrow lesions in patient 7,
we offered systemic TAT to patient 8 with disseminated bone
marrow carcinosis in whom PRRT with beta particles was
considered contraindicated. While treatment response in
non-solid lesions is not evaluable according to RECIST
criteria, we are able to report a remarkable low acute haema-
tological toxicity. This is in accordance to the concept of cell
selective micro-dosing due to the short path length (about two
cell diameters) of an alpha particle, and consistent with the
experience with CD33 targeted radionuclide therapy of
AML. A 131I-labelled anti-CD33-mAb translated into a
myeloablative bone marrow dose [26]. In contrast, with
213Bi-labelled anti-CD33-mAb it was possible to induce a
reduction of bone marrow blasts with tolerable haematologi-
cal toxicity [27].
We found a relevant decline in both TER and GFR in all
our patients treated with TAT. In a study evaluating renal
toxicity after 90Y-DOTATOC or 177Lu-DOTATATE therapy,
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of 23 patients who received a median dose of 12.2 GBq
90Y-DOTATOC, 12 showed a creatinine clearance loss of
>5 % and 8 a loss of >10 %, and of 5 patients who received
a median dose of 23.2 GBq 177Lu-DOTATATE, 3 showed a
creatinine clearance loss of >5 % and 2 a loss of >10 % at
1 year. Based on these data, a kidney tolerance threshold of
28 Gy was recommended [28]. In our patients the kidney
tolerance dose had already been consumed during the exten-
sive pretreatment with beta-emitting PRRT, and thus a higher
grade of kidney impairment was expected. However, during
the follow-up of 2 years, none of our patients developed
severe kidney failure requiring dialysis. Nevertheless, none
of our patients showed pathological renal test results when
TAT was started. The toxicity of TAT could be even more
severe in patients with renal risk factors or previously dam-
aged kidneys, and therefore we still need to be cautious in the
use of TAT in patients with a long life expectancy.
In a preclinical investigation 213Bi-DOTA-PESIN was
compared with 177Lu-DOTA-PESIN [29]. No tubular degen-
eration but rather glomerulopathy was observed with
177Lu-DOTA-PESIN. In contrast, with 213Bi-DOTA-
PESIN, tubular degeneration was the leading pathology.
Following glomerular filtration, radiolabelled peptides are
reabsorbed and trapped in the tubular cells. Due to the short
range of alpha particles the authors suggested that mainly
tubular cells were irradiated. In contrast, beta particles may
reach the radiosensitive glomeruli. Therefore, we monitored
kidney function with dedicated 99mTc-MAG3 and 51Cr-EDTA
tests for TER and GFR, respectively. With a 40 % decline in
TER and a 30 % decline in GFR during a 2-year period in our
patients the tubular impairment was only slightly higher than
glomerular toxicity. This would support the assumption that
some of the toxicity can be attributed to the preceding beta-
PRRT. However, it is not legitimate to compare the kidney
toxicity of first-line beta-PRRT with the toxicity of alpha-
PRRT in pretreated patients and overlap with kidney toxicity
from the earlier therapy. After 90Y-DOTATOC treatment kid-
ney failure after a latency period of even 15 months has been
reported previously [30].
For a long time alpha emitters have been considered the
perfect fit for Ehrlich’s “magic bullet” approach to cell-
selective cancer therapy [31]. The advantage of alpha over
beta radiation in therapeutic nuclear medicine has already
been demonstrated in preclinical studies [6]. Octreotide ana-
logues labelled with alpha particle emitters have also shown a
reasonable therapeutic range in animals [7, 8]. However, until
now the limited availability of these radioisotopes has been a
key challenge for the transfer to clinical use. To date, the
required 225Ac to build a high-activity generator system to
provide sufficient 213Bi for clinical use has only been possible
by combining the maximum activity currently available from
the three producers, i.e. Oak Ridge National Laboratory
(Oak Ridge, TN), the Institute for Transuranium Elements
(Karlsruhe, Germany) and the Institute for Physics and
Power Engineering (Obninsk, Russia). However, the recent
development of accelerator-driven processes that allow pro-
duction of the mother nuclide for 225Ac/213Bi generators in
practically unlimited amounts may overcome these supply
limitations in the near future [32, 33].
Recently the use of 223Ra, another alpha-emitting radionu-
clide and an inherent bone seeker, has led to improved sur-
vival in patients suffering from bone metastases of prostate
cancer [34]. However, the stable linkage of divalent 223Ra(II)
to antibodies or other carrier molecules has not been success-
ful. We introduced the chelatable, alpha-emitting radionuclide
213Bi to clinical PRRT targeting the somatostatin receptors of
NET patients. The chelate molecule DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) has already
been linked to a variety of tumour-targeting molecules, and
therefore our approach could be easily transferable to other
targeted therapies in oncology.
In the first preclinical phase of our study, we had to
develop suitable labelling conditions for 213Bi-DOTATOC.
Finally, a reliable protocol for the synthesis of clinical
doses of 213Bi-DOTATOC was successfully established
(see Materials and methods section). The 225Ac/213Bi genera-
tor system developed at the Institute for Transuranium
Elements was demonstrated to be able to reliably provide
single doses of up to 2 GBq 213Bi-DOTATOC per injection.
Labelling yields of 213Bi-DOTATOC reliably exceeded 99 %.
While the clinical application of alpha emitters promises
advantages due to the short path length and the high linear
energy transfer of the emitted particle (Fig. 1), there are also
some challenges associated with the available nuclides. The
main route (98%) of 213Bi decay involves an initial beta decay
with 435 keVmean energy immediately (delay 3.7μs) follow-
ed by the therapeutic alpha decay to 209Pb which is a beta
emitter with 198 keV mean energy (half-life 3.2 h) and decays
to quasistable 209Bi (Supplementary Fig. 2). While the beta
emissions contribute only about 8 % to the absorbed tissue
dose [35], the bremsstrahlung following the beta decay com-
promise the inherent imaging abilities of 213Bi that is based on
the emission of 440 keV gamma ray with an emission prob-
ability of 26 % per decay. Due to the recoil of the alpha
particle, 209Pb (3.2 h) is expected to leave the DOTA chelate
and eventually even the target tissue to redistribute to nontar-
get organs, thus translating into high background noise.
The short half-life of 213Bi (45.6 min) is also challenging in
regard to the limited temporal resolution of conventional
scintigraphy. In addition, the spatial resolution of a gamma
camera is insufficient to provide reliable microdosimetry. In a
post-mortem autoradiography evaluation of a subject exposed
to the alpha emitter 232Th, microscopic “hot spots” with
doses up to 50-fold higher than those assuming a homoge-
neous organ biodistribution were found [36]. Therefore the
440 keV gamma images of 213Bi-DOTATOC are not
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sufficient for imaging-based dosimetry. However, the value of
pretherapeutic dosimetry is still a controversial debate for
radioiodine therapy and even 124I-PET-based treatment regi-
mens have not been shown to be superior to the use of
standard activities [37]. Therefore, dose finding in our patients
was done in a similar empirical manner to the procedure used
for the establishment of new chemotherapeutics with escalat-
ing activity fractions until dose-limiting toxicity was
observed.
Another challenge for blood and bone marrow dosimetry is
the redistribution of the unstable, beta-emitting decay product
209Pb, which might partially leave the tumour tissue. Free Pb
is known to accumulate in erythrocytes which can translate to
a perfusion-dependent increase in bonemarrow radiation [38].
However, the decay chain of clinically used 223Ra and 224Ra
includes the formation of 211Pb (half-life 36.1 min) or 212Pb
(half-life 10.6 h), which should show redistribution patterns
similar to that of 209Pb, and is followed by an additional alpha
emission in the succeeding decay schema. Nevertheless, they
are not associated with remarkable bone marrow toxicity [34,
38]. In contrast, the energy transfer from the beta radiation of
209Pb might be considered almost negligible, and also the long
period to onset of anaemia observed in the follow-up of
patients receiving TATcontradicts the thesis of directly related
red blood cell or bone marrow toxicity. However, it would be
of particular interest to develop dosimetry tools that might
enable absorbed doses to be modelled and probabilities pre-
dicted for response and toxicity prior to TAT.
Haematological and kidney toxicity are the limiting factors
in the use of 90Y/177Lu-DOTATOC. With 213Bi-DOTATOC
acute haematological toxicity was moderate even in a patient
with disseminated bone marrow involvement (Fig. 7). This is
in accordance with the observations of the ALSYMPCA trial.
The haematological toxicity of the bone-seeking alpha emitter
223Ra was not significantly higher than that of placebo [34]. In
contrast, bone seekers labelled with a beta emitter can cause a
relevant rate of grade-III thrombocytopenia and leucopenia
[39]. MDS/AML was observed in one patient 2 years after
initiation of TAT. However, this patient was heavily pretreated
with 16 GBq 90Y-DOTATOC and 24 GBq 177Lu-DOTATOC
in multiple cycles starting 5 years before the onset of MDS.
MDS/AML has been found in 4.2 % of patients treated with
90Y-Zevalin during long-term follow-up with a mean latency
of 4.8 years [40]. This is also in accordance with single case
reports of MDS/AML from beta-PRRT centres in Rotterdam
and Bonn [3, 41]. Therefore, the MDS/AML that occurred in
our patient matches well the typical latency period for a
90Y-related secondary malignancy.
With a follow-up period of 3 years, no myeloproliferative
disorders were found in patients who had received the bone-
seeking alpha emitter 223Ra [34]. Nevertheless, alpha emitters
produce a high rate of double-strand DNA breaks and might
be associated with a higher number of secondary neoplasias.
Therefore, thorough long-term follow-up will be pivotal once
TAT is evaluated in prospective clinical trials for first-line or
second-line therapy, especially in patients with a good prog-
nosis. Our reported experience is not sufficient to conclude
that alpha-emitting radiopharmaceuticals are superior to beta-
emitting radiopharmaceuticals in general. For the reported
patients, the duration of tumour control with the preceding
90Y/177Lu-DOTATOC therapy was up to 3 years (Table 1),
and the follow-up in patients receiving TATwas only 2 years
at the time of this report. However, we successfully demon-
strated the feasibility of overcoming beta resistance with alpha
emitters as an additional treatment line.
Conclusion
All patients reported in this investigation were in different chal-
lenging situations when receiving TAT with 213Bi-DOTATOC.
TAT was shown to be able to overcome resistance against beta
radiation and resulted in a high number of long-lasting anti–
tumour responses. 213Bi-DOTATOC was associated with mod-
erate acute haematological toxicity, even in a patient with highly
disseminated bone marrow involvement. Chronic kidney im-
pairment remained in the acceptable range, and no other organ
toxicity was observed. Bringing together the possibility of pro-
ducing the alpha emitter 213Bi in sufficient quantities to support
universal clinical application in combination with chelate-
conjugated targetingmolecules, our results with TATmight open
new avenues in therapeutic nuclear medicine.
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